Encompass Health Past Earnings Performance
Past criteria checks 4/6
Encompass Health's earnings have been declining at an average annual rate of -2.2%, while the Healthcare industry saw earnings growing at 11.6% annually. Revenues have been declining at an average rate of 0.1% per year. Encompass Health's return on equity is 21.3%, and it has net margins of 7.6%.
Key information
-2.2%
Earnings growth rate
-2.6%
EPS growth rate
| Healthcare Industry Growth | 11.6% |
| Revenue growth rate | -0.1% |
| Return on equity | 21.3% |
| Net Margin | 7.6% |
| Next Earnings Update | 07 Feb 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Encompass Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 4,692 | 355 | 247 | 0 |
| 30 Jun 23 | 4,574 | 334 | 233 | 0 |
| 31 Mar 23 | 4,450 | 279 | 213 | 0 |
| 31 Dec 22 | 4,349 | 255 | 209 | 0 |
| 30 Sep 22 | 4,254 | 232 | 213 | 0 |
| 30 Jun 22 | 4,175 | 242 | 217 | 0 |
| 31 Mar 22 | 3,844 | 253 | 223 | 0 |
| 31 Dec 21 | 4,015 | 296 | 229 | 0 |
| 30 Sep 21 | 4,187 | 316 | 226 | 0 |
| 30 Jun 21 | 4,350 | 318 | 232 | 0 |
| 31 Mar 21 | 4,693 | 304 | 240 | 0 |
| 31 Dec 20 | 3,566 | 193 | 213 | 0 |
| 30 Sep 20 | 4,614 | 265 | 263 | 0 |
| 30 Jun 20 | 4,602 | 285 | 278 | 0 |
| 31 Mar 20 | 4,663 | 342 | 312 | 0 |
| 31 Dec 19 | 4,605 | 358 | 329 | 0 |
| 30 Sep 19 | 4,517 | 317 | 319 | 0 |
| 30 Jun 19 | 4,423 | 308 | 315 | 0 |
| 31 Mar 19 | 4,355 | 309 | 292 | 0 |
| 31 Dec 18 | 4,277 | 290 | 298 | 0 |
| 30 Sep 18 | 4,190 | 339 | 285 | 0 |
| 30 Jun 18 | 4,104 | 316 | 274 | 0 |
| 31 Mar 18 | 4,003 | 288 | 271 | 0 |
| 31 Dec 17 | 3,914 | 271 | 245 | 0 |
| 30 Sep 17 | 3,841 | 260 | 236 | 0 |
| 30 Jun 17 | 3,771 | 256 | 226 | 0 |
| 31 Mar 17 | 3,710 | 256 | 209 | 0 |
| 31 Dec 16 | 3,643 | 247 | 205 | 0 |
| 30 Sep 16 | 3,576 | 228 | 198 | 0 |
| 30 Jun 16 | 3,432 | 217 | 189 | 0 |
| 31 Mar 16 | 3,280 | 198 | 176 | 0 |
| 31 Dec 15 | 3,116 | 181 | 175 | 0 |
| 30 Sep 15 | 2,857 | 173 | 168 | 0 |
| 30 Jun 15 | 2,678 | 172 | 171 | 0 |
| 31 Mar 15 | 2,520 | 204 | 173 | 0 |
| 31 Dec 14 | 2,374 | 208 | 157 | 0 |
| 30 Sep 14 | 2,336 | 144 | 175 | 0 |
| 30 Jun 14 | 2,303 | 148 | 170 | 0 |
| 31 Mar 14 | 2,266 | 228 | 171 | 0 |
| 31 Dec 13 | 2,247 | 229 | 176 | 0 |
| 30 Sep 13 | 2,224 | 293 | 168 | 0 |
| 30 Jun 13 | 2,198 | 281 | 177 | 0 |
| 31 Mar 13 | 2,168 | 161 | 179 | 0 |
Quality Earnings: E2HC34 has high quality earnings.
Growing Profit Margin: E2HC34's current net profit margins (7.6%) are higher than last year (5.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: E2HC34's earnings have declined by 2.2% per year over the past 5 years.
Accelerating Growth: E2HC34's earnings growth over the past year (53.2%) exceeds its 5-year average (-2.2% per year).
Earnings vs Industry: E2HC34 earnings growth over the past year (53.2%) exceeded the Healthcare industry -3%.
Return on Equity
High ROE: Whilst E2HC34's Return on Equity (21.3%) is high, this metric is skewed due to their high level of debt.